Articles by Prof. Marcus Webb
Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026
Pulse Biosciences achieves 100% procedural success in atrial fibrillation treatment study with 95 evaluable patients at 6 months, presenting data at Heart Rhythm 2026.
Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026
Acurx presents promising data showing DNA pol IIIC inhibitors effectively treat MRSA infections while preserving gut microbiome, addressing key antibiotic concern.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
FDA approves LANGLARA (insulin glargine-aldy) as interchangeable biosimilar to Lantus for diabetes treatment in adults and pediatric patients.
Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC
Nuvation Bio reports $18.5M Q1 2026 revenue for IBTROZI (taletrectinib) with majority of 200 new patients being TKI-naïve ROS1+ NSCLC cases.
Pharmaceutical Manufacturing Software Market to Reach $7.87 Billion by 2030, Driven by 15.8% CAGR Growth
Pharmaceutical manufacturing software market grows from $3.82B to $4.43B in 2026 with 15.8% CAGR, projected to reach $7.87B by 2030 amid regulatory demands.
Bio-Rad Q1 2026 Results Show IVDR Compliance Costs Impact European Diagnostics Operations
Bio-Rad reports Q1 2026 financial results highlighting increased costs from EU IVDR compliance and product portfolio rationalization in diagnostics market.
Norgine Receives European Approval for XOLREMDI (Mavorixafor), First WHIM Syndrome Treatment in EU
Norgine's XOLREMDI becomes the first authorized treatment for WHIM syndrome in Europe, marking a breakthrough for ultra-rare immunodeficiency patients.
COFEPRIS Approval Pathway: Transforming Generic Drugs Market in Mexico
Explore the COFEPRIS approval pathway and its impact on the generic drugs market in Mexico, improving access to vital medications such as Metformin.
NICE Technology Appraisals: Impact on UK Pharma Market Access Post-Brexit
This article delves into the implications of NICE Technology Appraisals on the UK pharmaceutical market, focusing on drug XYZ and its access challenges after Brexit.
SAHPRA Biosimilars Approval: Trends and Impact on Affordable Medicine Access
This article delves into SAHPRA's recent biosimilars approvals, highlighting trends and their significant role in enhancing access to affordable medications.
Saudi Arabian Pharmaceutical Market: Impact of SFDA Expedited Drug Approvals
This article examines how the SFDA's expedited drug approvals are transforming the Saudi Arabian pharmaceutical landscape, improving access to essential treatments.
Alzheimer's Clinical Trial Failures: Novo Nordisk's Semaglutide Phase 3 Outcome & Market Impact
Novo Nordisk's Semaglutide Phase 3 trial for Alzheimer's has failed, raising concerns about future research and market dynamics in neurodegenerative treatments.
Small Molecule API Market Projected to Reach $202.53 Billion by 2036 as Generic Drug Demand Surges
Small molecule API market set to hit $202.53 billion by 2036, driven by generic drug demand and oncology pipeline expansion across global markets.
Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026
Novo Nordisk unveils new clinical data on Wegovy for women with obesity and next-generation weight loss treatments at European Congress on Obesity in Istanbul.
HIV Clinical Trials Africa: IMPALA Trial Validates CAB/RPV LA Efficacy
The IMPALA trial confirms the efficacy of CAB/RPV LA in treating HIV, showcasing its potential to improve patient care in Africa.
Elanco's Negasunt and Tanidil Receive FDA Emergency Authorization for New World Screwworm Treatment in Livestock
FDA grants emergency use authorization for Elanco's Negasunt Powder and Tanidil to combat New World screwworm in livestock, preparing U.S. veterinarians.
NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025
This article delves into the latest NMPA-approved antibody-drug conjugates (ADCs) for lung cancer, examining trends and clinical insights shaping 2025.
FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights
Explore the latest insights on FDA-approved Sotorasib and Adagrasib for treating KRAS G12C NSCLC, transforming lung cancer therapy.
Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline
Oncotelic Therapeutics provides corporate update on strategic partnerships to advance clinical-stage cancer treatments and expand market reach.
African Medicines Agency: Progress in Harmonizing Regulatory Standards Across Africa
The African Medicines Agency is making strides in harmonizing regulatory standards, enhancing the safety and efficacy of medicines like antimalarials across the continent.